RT @CritCareReviews: Is neuromuscular blockade beneficial in ARDS? @Terri_Hough presents the #ROSEtrial and @dfmcauley delivers an editori…
RT @CritCareReviews: Is neuromuscular blockade beneficial in ARDS? @Terri_Hough presents the #ROSEtrial and @dfmcauley delivers an editori…
RT @CritCareReviews: Is neuromuscular blockade beneficial in ARDS? @Terri_Hough presents the #ROSEtrial and @dfmcauley delivers an editori…
RT @CritCareReviews: Is neuromuscular blockade beneficial in ARDS? @Terri_Hough presents the #ROSEtrial and @dfmcauley delivers an editori…
Is neuromuscular blockade beneficial in ARDS? @Terri_Hough presents the #ROSEtrial and @dfmcauley delivers an editorial. https://t.co/CsOmOqA4r6 This, plus the rest of the best of 2019 critical care trials, at #CCR20 https://t.co/YXMWcvi8iC https://t.co/
RT @ATSfellows: When should I use neuromuscular blockade in moderate/ severe ARDS? Link podcast: https://t.co/GuTyI3DjuY Link @NEJM artic…
Early NM Blockade in the Acute Respiratory Distress Syndrome https://t.co/5sXVvueFww
RT @CritCareReviews: ACURASYS reported benefit with neuromuscular blockade in ARDS, while the subsequent ROSE trial did not. Why the diffe…
RT @CritCareReviews: ACURASYS reported benefit with neuromuscular blockade in ARDS, while the subsequent ROSE trial did not. Why the diffe…
RT @CritCareReviews: ACURASYS reported benefit with neuromuscular blockade in ARDS, while the subsequent ROSE trial did not. Why the diffe…
RT @iwashyna: .@Terri_Hough is going to knock this out of the park... https://t.co/VHL0JV6g8o
RT @CritCareReviews: ACURASYS reported benefit with neuromuscular blockade in ARDS, while the subsequent ROSE trial did not. Why the diffe…
RT @iwashyna: .@Terri_Hough is going to knock this out of the park... https://t.co/VHL0JV6g8o
RT @iwashyna: .@Terri_Hough is going to knock this out of the park... https://t.co/VHL0JV6g8o
RT @CritCareReviews: ACURASYS reported benefit with neuromuscular blockade in ARDS, while the subsequent ROSE trial did not. Why the diffe…
RT @CritCareReviews: ACURASYS reported benefit with neuromuscular blockade in ARDS, while the subsequent ROSE trial did not. Why the diffe…
RT @CritCareReviews: ACURASYS reported benefit with neuromuscular blockade in ARDS, while the subsequent ROSE trial did not. Why the diffe…
RT @iwashyna: .@Terri_Hough is going to knock this out of the park... https://t.co/VHL0JV6g8o
RT @CritCareReviews: ACURASYS reported benefit with neuromuscular blockade in ARDS, while the subsequent ROSE trial did not. Why the diffe…
.@Terri_Hough is going to knock this out of the park...
RT @CritCareReviews: ACURASYS reported benefit with neuromuscular blockade in ARDS, while the subsequent ROSE trial did not. Why the diffe…
RT @CritCareReviews: ACURASYS reported benefit with neuromuscular blockade in ARDS, while the subsequent ROSE trial did not. Why the diffe…
RT @CritCareReviews: ACURASYS reported benefit with neuromuscular blockade in ARDS, while the subsequent ROSE trial did not. Why the diffe…
RT @CritCareReviews: ACURASYS reported benefit with neuromuscular blockade in ARDS, while the subsequent ROSE trial did not. Why the diffe…
RT @CritCareReviews: ACURASYS reported benefit with neuromuscular blockade in ARDS, while the subsequent ROSE trial did not. Why the diffe…
ACURASYS reported benefit with neuromuscular blockade in ARDS, while the subsequent ROSE trial did not. Why the difference and why does it matter? @Terri_Hough to present the ROSE trial at #CCR20 and @dfmcauley to editorialise https://t.co/av3Zc3k6Ba h
RT @iamyourgasman: @charlot_summers NMB in #ards it was good in France is this still good? Analysing the ROSE study https://t.co/W2Mh3et0FV…
@charlot_summers NMB in #ards it was good in France is this still good? Analysing the ROSE study https://t.co/W2Mh3et0FV #ACCConfUK
RT @ATSfellows: When should I use neuromuscular blockade in moderate/ severe ARDS? Link podcast: https://t.co/GuTyI3DjuY Link @NEJM artic…
Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome | NEJM https://t.co/cOPeRymSvS
RT @gsmartinmd: Interestingly, the ROSE study, which heavily relied on ICU & EM collaboration, enrolled #ARDS subjects faster than any prio…
RT @gsmartinmd: Interestingly, the ROSE study, which heavily relied on ICU & EM collaboration, enrolled #ARDS subjects faster than any prio…
RT @gsmartinmd: Interestingly, the ROSE study, which heavily relied on ICU & EM collaboration, enrolled #ARDS subjects faster than any prio…
Interestingly, the ROSE study, which heavily relied on ICU & EM collaboration, enrolled #ARDS subjects faster than any prior study and nearly double the proportion (20% of screened patients) #CHEST2019 https://t.co/jVqLqHuHow
The ROSE study did not find benefits to paralysis in #ARDS patients #CHEST2019 https://t.co/jVqLqHuHow https://t.co/XCyDA3s8jZ
Ещё один заход на вечную тему о применении миорелаксантов при респираторном дистресс синдроме. Исследование остановлено досрочно из за одинаковой госпитальной летальности: 42,5% в группе с релаксантами и 43,8 в контрольной. https://t.co/56X7F47B0E
RT @AGMRRT: Welcome to @SCCM #journalclub, discussing the ROSE trial of Early Neuromuscular Blockade in the Acute Respiratory Distress Synd…
RT @AGMRRT: Welcome to @SCCM #journalclub, discussing the ROSE trial of Early Neuromuscular Blockade in the Acute Respiratory Distress Synd…
RT @AGMRRT: Welcome to @SCCM #journalclub, discussing the ROSE trial of Early Neuromuscular Blockade in the Acute Respiratory Distress Synd…
RT @AGMRRT: Welcome to @SCCM #journalclub, discussing the ROSE trial of Early Neuromuscular Blockade in the Acute Respiratory Distress Synd…
Welcome to @SCCM #journalclub, discussing the ROSE trial of Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome published in @NEJM. Please use the hashtag #respiratoryICU! https://t.co/rGPnXgHTnl
10-02-19 @ 8:45am Journal club by #DrWilliamRichter ; #ROSE 🌹 Trial https://t.co/M2oCgwUyKg . The future depends on what we do in the present. MKG
RT @donnatanner815: Calling #LungNerds to join @AGMRRT #RespiratoryICU @SCCM 10/1 8pEST for #JournalClub ROSE Trial #ARDS @kdlamb1 @…
RT @donnatanner815: Calling #LungNerds to join @AGMRRT #RespiratoryICU @SCCM 10/1 8pEST for #JournalClub ROSE Trial #ARDS @kdlamb1 @…
RT @donnatanner815: Calling #LungNerds to join @AGMRRT #RespiratoryICU @SCCM 10/1 8pEST for #JournalClub ROSE Trial #ARDS @kdlamb1 @…
RT @donnatanner815: Calling #LungNerds to join @AGMRRT #RespiratoryICU @SCCM 10/1 8pEST for #JournalClub ROSE Trial #ARDS @kdlamb1 @…
RT @donnatanner815: Calling #LungNerds to join @AGMRRT #RespiratoryICU @SCCM 10/1 8pEST for #JournalClub ROSE Trial #ARDS @kdlamb1 @…
RT @donnatanner815: Calling #LungNerds to join @AGMRRT #RespiratoryICU @SCCM 10/1 8pEST for #JournalClub ROSE Trial #ARDS @kdlamb1 @…
Calling #LungNerds to join @AGMRRT #RespiratoryICU @SCCM 10/1 8pEST for #JournalClub ROSE Trial #ARDS @kdlamb1 @abribriesco43 @CCF_PCCM @emireles_c @MadisonRRT https://t.co/c5a8KZpyWh
RT @donnatanner815: ATTN: #LungNerds that ♥️ #ARDS 10/1 @8p EST #JournalClub for #RespiratoryICU @SCCM hosted by @AGMRRT @abribriesco4…
RT @donnatanner815: #RespiratoryICU @SCCM Is having our Oct #JournalClub on 10/01 hosted by @AGMRRT #ARDS #LungNerd @abribriesco43 @CC…
RT @donnatanner815: ATTN: #LungNerds that ♥️ #ARDS 10/1 @8p EST #JournalClub for #RespiratoryICU @SCCM hosted by @AGMRRT @abribriesco4…
RT @donnatanner815: ATTN: #LungNerds that ♥️ #ARDS 10/1 @8p EST #JournalClub for #RespiratoryICU @SCCM hosted by @AGMRRT @abribriesco4…
Please join me on October 1 at 8 pm eastern time to discuss the ROSE trial as part of @SCCM respiratory care section journal club! @DukePCCM @AlexRotta @SapnaKmd @SCCMPresident @kdlamb1 @jcink17 #respiratoryICU #journalclub
ATTN: #LungNerds that ♥️ #ARDS 10/1 @8p EST #JournalClub for #RespiratoryICU @SCCM hosted by @AGMRRT @abribriesco43 @CCF_PCCM @siddharth_dugar @kdlamb1 @MadisonRRT https://t.co/c5a8KZpyWh
RT @ATSCritCare: Read the full trial: https://t.co/8tvh1Qngy9
RT @ATSCritCare: Must-listen podcast for critical care. Insights from the leaders of the ROSE study, Derek Angus and Marc Moss, on when to…
Pretty interesting split! Do you think it reflects practice? 30% routine use of paralytics in ARDS, 50% occasional, and 7% never? I realized I was in the "routine" use for severe ARDS- as a step up before proning. Probably delaying proning which is more i
RT @docsrai: No 90-day mortality difference with early NMB use in moderate to sever ARDS when high PEEP used https://t.co/iCYnFi2YPk
RT @laxswamy: Journal club today on the ROSE trial for early neuromuscular blockade in ARDS. What's your practice w NMB/paralysis in ARDS?…
RT @laxswamy: Journal club today on the ROSE trial for early neuromuscular blockade in ARDS. What's your practice w NMB/paralysis in ARDS?…
RT @laxswamy: Journal club today on the ROSE trial for early neuromuscular blockade in ARDS. What's your practice w NMB/paralysis in ARDS?…
No 90-day mortality difference with early NMB use in moderate to sever ARDS when high PEEP used https://t.co/iCYnFi2YPk
How do you use NMBAs in ARDs? Survey 👇🏻 https://t.co/kVXzncpSaQ
RT @donnatanner815: #RespiratoryICU @SCCM Is having our Oct #JournalClub on 10/01 hosted by @AGMRRT #ARDS #LungNerd @abribriesco43 @CC…
Journal club today on the ROSE trial for early neuromuscular blockade in ARDS. What's your practice w NMB/paralysis in ARDS? #pulmcc #ICU https://t.co/QsQhySSjKh @NEJM
Last one was a hit!
#RespiratoryICU @SCCM Is having our Oct #JournalClub on 10/01 hosted by @AGMRRT #ARDS #LungNerd @abribriesco43 @CCF_PCCM @siddharth_dugar @kdlamb1 @MadisonRRT @emireles_c https://t.co/c5a8KZpyWh
@suziechaps1 @icu_dave @sicsmembers @iceman_ex @ICS_updates @ESICM 1. ROSE Study https://t.co/hNudhlySE9 Examining NMB in severe ARDS (see ACURASYS): 48h Cis-atrac > no difference in 90d mortality, in-hospital mortality > stopped early. Unblinded, hi
RT @ATSfellows: When should I use neuromuscular blockade in moderate/ severe ARDS? Link podcast: https://t.co/GuTyI3DjuY Link @NEJM artic…
RT @ATSCritCare: Must-listen podcast for critical care. Insights from the leaders of the ROSE study, Derek Angus and Marc Moss, on when to…
RT @ATSCritCare: Must-listen podcast for critical care. Insights from the leaders of the ROSE study, Derek Angus and Marc Moss, on when to…
RT @ATSCritCare: Must-listen podcast for critical care. Insights from the leaders of the ROSE study, Derek Angus and Marc Moss, on when to…
RT @ATSCritCare: Must-listen podcast for critical care. Insights from the leaders of the ROSE study, Derek Angus and Marc Moss, on when to…
RT @ATSCritCare: Must-listen podcast for critical care. Insights from the leaders of the ROSE study, Derek Angus and Marc Moss, on when to…
RT @mtniehaus: Great synopsis of the @NEJM #rosetrial by @PittCCM chair Derek Angus and co-PI Dr Moss - worth a listen https://t.co/lRkMWI7…
RT @ATSCritCare: Must-listen podcast for critical care. Insights from the leaders of the ROSE study, Derek Angus and Marc Moss, on when to…
RT @ATSCritCare: Must-listen podcast for critical care. Insights from the leaders of the ROSE study, Derek Angus and Marc Moss, on when to…
RT @ATSfellows: When should I use neuromuscular blockade in moderate/ severe ARDS? Link podcast: https://t.co/GuTyI3DjuY Link @NEJM artic…
RT @ATSfellows: When should I use neuromuscular blockade in moderate/ severe ARDS? Link podcast: https://t.co/GuTyI3DjuY Link @NEJM artic…
RT @ATSCritCare: Must-listen podcast for critical care. Insights from the leaders of the ROSE study, Derek Angus and Marc Moss, on when to…
RT @ATSCritCare: Must-listen podcast for critical care. Insights from the leaders of the ROSE study, Derek Angus and Marc Moss, on when to…
RT @mtniehaus: Great synopsis of the @NEJM #rosetrial by @PittCCM chair Derek Angus and co-PI Dr Moss - worth a listen https://t.co/lRkMWI7…
RT @ATSfellows: When should I use neuromuscular blockade in moderate/ severe ARDS? Link podcast: https://t.co/GuTyI3DjuY Link @NEJM artic…
RT @ATSCritCare: Must-listen podcast for critical care. Insights from the leaders of the ROSE study, Derek Angus and Marc Moss, on when to…
Great synopsis of the @NEJM #rosetrial by @PittCCM chair Derek Angus and co-PI Dr Moss - worth a listen
RT @ATSCritCare: Must-listen podcast for critical care. Insights from the leaders of the ROSE study, Derek Angus and Marc Moss, on when to…
RT @ATSfellows: When should I use neuromuscular blockade in moderate/ severe ARDS? Link podcast: https://t.co/GuTyI3DjuY Link @NEJM artic…
RT @ATSCritCare: Must-listen podcast for critical care. Insights from the leaders of the ROSE study, Derek Angus and Marc Moss, on when to…
RT @ATSCritCare: Must-listen podcast for critical care. Insights from the leaders of the ROSE study, Derek Angus and Marc Moss, on when to…
RT @ATSCritCare: Must-listen podcast for critical care. Insights from the leaders of the ROSE study, Derek Angus and Marc Moss, on when to…
RT @ATSfellows: When should I use neuromuscular blockade in moderate/ severe ARDS? Link podcast: https://t.co/GuTyI3DjuY Link @NEJM artic…
RT @ATSfellows: When should I use neuromuscular blockade in moderate/ severe ARDS? Link podcast: https://t.co/GuTyI3DjuY Link @NEJM artic…
RT @ATSCritCare: Must-listen podcast for critical care. Insights from the leaders of the ROSE study, Derek Angus and Marc Moss, on when to…
RT @ATSCritCare: Must-listen podcast for critical care. Insights from the leaders of the ROSE study, Derek Angus and Marc Moss, on when to…
RT @ATSCritCare: Must-listen podcast for critical care. Insights from the leaders of the ROSE study, Derek Angus and Marc Moss, on when to…